

AD_____

AWARD NUMBER: W81XWH-07-1-0044

TITLE: Identification of the Transformational Properties and Transcriptional Targets of the Oncogenic SRY Transcription Factor SOX4

PRINCIPAL INVESTIGATOR: Christopher Scharer

CONTRACTING ORGANIZATION: Emory University
Atlanta, GA 30322

REPORT DATE: January 2010

TYPE OF REPORT: Annual Summary

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE 1 January 2010		2. REPORT TYPE Annual Summary		3. DATES COVERED 11 Dec 2006 – 10 Dec 2009	
4. TITLE AND SUBTITLE Identification of the Transformational Properties and Transcriptional Targets of the Oncogenic SRY Transcription Factor SOX4				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER W81XWH-07-1-0044	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Christopher Scharer E-Mail: cdschar@emory.edu				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Emory University Atlanta, GA 30322				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT SOX4 is a critical developmental transcription factor in vertebrates and is required for precise proliferation and differentiation in multiple tissues. SOX4 has also been implicated in tumorigenesis of multiple tumor types and has been shown by our lab to be upregulated in prostate cancer. However, the exact molecular role and the genes SOX4 transcriptionally influences remain unknown. Using chromatin immunoprecipitation coupled to DNA microarrays (ChIP-chip) we have identified 282 high confidence SOX4 target genes and 3600 genomic binding sites. We have also used a unique protein binding, double-stranded DNA microarray to determine a novel SOX4 position-weight matrix for in silico binding site searches. Direct targets of SOX4 include key cellular regulators such as EGFR, Tenascin C, Frizzled-5 and Patched-1. In addition, SOX4 impacts other transcriptional networks through regulation of 23 transcription factors. We also show that SOX4 impacts the microRNA-processing pathway through direct regulation of Dicer and Argonaute 1. For the first time, these data provide a snapshot of the global transcriptional regulatory network of SOX4 in prostate cancer. In tandem to molecular studies of SOX4 we have developed mice that harbor a prostate specific deletion of SOX4. Initial studies of our first mouse suggest that loss of SOX4 in the prostate has detrimental effects on fertility. While preliminary, these findings are exciting and hit at a previously unknown biological role for SOX4.					
15. SUBJECT TERMS ChIP-chip, SOX4, Prostate Cancer, Protein-binding microarray, mouse models					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT UU	18. NUMBER OF PAGES 23	19a. NAME OF RESPONSIBLE PERSON USAMRMC
a. REPORT U	b. ABSTRACT U	c. THIS PAGE U			19b. TELEPHONE NUMBER (include area code)

Table of Contents

	<u>Page</u>
Introduction.....	4
Body.....	5
Key Research Accomplishments.....	6
Reportable Outcomes.....	6
Conclusion.....	7
References.....	8
Appendices.....	9

Introduction:

SOX4 is a critical developmental transcription factor and is required for precise differentiation and proliferation in multiple tissues. SOX4 is a 47-kDa protein that is encoded by a single exon and contains a conserved high mobility group (HMG) DNA-binding domain (DBD) related to the TCF/LEF family of transcription factors. Our lab has previously shown SOX4 mRNA and protein to be overexpressed in prostate cancer, and this expression is correlated with increasing Gleason score. Other labs have shown SOX4 mRNA to be overexpressed in other tumors such as leukemia, melanoma, glioblastoma and bladder carcinomas. However, despite this knowledge little is known of the direct transcriptional targets of SOX4, and how misregulation of these networks affects human cancers and development. The goal of this research is to determine the transcriptional target genes of SOX4 and to determine SOX4's role in normal murine prostate development. To determine the direct transcriptional targets on a global scale we performed chromatin immunoprecipitation coupled to DNA microarrays. We used human promoter arrays from NimbleGen, Inc. that tiled roughly 5 kb of promoter and intronic sequence for 25,000 known transcripts. In total, the array tiled 110 Mb of DNA. Using this technique we were able to determine the genes with SOX4 bound at their promoter in living prostate cancer cells. Furthermore, expression profiling of prostate cancer cells overexpressing either SOX4 or a control vector identified those genes that are transcriptionally regulated by SOX4. We have also obtained a mouse containing the endogenous SOX4 locus flanked by LOXP sites. Crossing of SOX4 floxed mice to mice that express CRE recombinase specifically in the prostate, will enable the prostate specific deletion of SOX4. This information will determine if SOX4 is required for the development of a functional prostate in mice and lend insight into the role of SOX4 in normal prostate biology. Determining the transcriptional targets and *in vivo* functions of SOX4 will contribute critical knowledge to the SOX4 field and further our understanding of SOX4's role in development and carcinogenesis.

Body:

AIM 1: Determine the Direct Transcriptional Targets of SOX4 on a Global Scale using a ChIP-chip and microarray approach.

Status: Completed

AIM1 has been described extensively in the previous Annual Reports and the publication describing the details of methods, data collection and various analyses can be found in Appendix III and (11).

In brief, using Chromatin immunoprecipitation coupled to high-throughput tiling microarrays (ChIP-chip), whole genome expression profiling and unique double-stranded DNA protein binding arrays we determined the genomic landscape of SOX4 binding sites, established the direct SOX4 transcriptional targets and calculated DNA binding preferences for the SOX4 transcription factor. We identified 3,600 genomic SOX4 binding sites regulating 3,470 possible genes. Intersecting ChIP-chip data with expression profiling we further classified 282 high-confidence genes as direct SOX4 transcriptional targets. Collaborating with Dr. Martha Bulyk we applied recombinant SOX4 protein to unique double-stranded DNA protein binding arrays to calculate the DNA binding preferences for SOX4 (1). SOX4 bound to the sequence RWYAAWRV (where R = A or G, Y = C or T, and V = G, A or C) that was calculated according to published protocols (1). At the time of publication we were only able to validate DICER1 as a transcriptional activation target of SOX4 at the protein level (Figure 1). Our ChIP-chip data unexpectedly suggested that SOX4 could influence the NOTCH pathway through upregulation of the NOTCH ligand DLL1, the activating protease ADAM10, and down stream NOTCH transcriptional target HES2. Increased SOX4 protein resulted in increased levels of cleaved, activated NOTCH protein (Figure 1). While these results are preliminary, we hypothesize that SOX4 can increase cellular levels of DLL1 and ADAM10, leading to stimulation of the NOTCH pathway. Active NOTCH signaling is known to drive breast tumors (2, 9, 10), melanomas (4), neuroblastomas (12), and as our lab has shown pituitary adenomas (5). Recently, alluding to a biological role for Future studies will investigate the precise role SOX4 plays in the NOTCH pathway including a possible unique role for SOX4 as a link between the NOTCH and WNT signaling pathways.

For a detailed discussion of these results see Appendix III and (11). All microarray data from AIM1 can be found at the author's website (<http://confac.emory.edu/>) or downloaded from NCBI's GEO database (GEO11915).

AIM2: Determine the effects of Loss or Overexpression in vivo

Status: Initiated, In Progress

SOX4 is required for the development and differentiation of multiple murine tissues (3, 6-8, 13). We hypothesize that deletion of SOX4, specifically in the prostate, will affect normal murine prostate development. Dr. Neal Copeland has provided us with mice that contain the endogenous SOX4 allele flanked by LOXP sites to facilitate CRE mediated deletion of SOX4. Here at Emory we already have a colony of mice containing the CRE transgene driven by the prostate specific Probasin promoter. Probasin is initially expressed at the onset of puberty (roughly two weeks of age) in all lobes of the prostate, seminal vesicles and a few other urogenital tract epithelial cells (15). We initially obtained SOX4^{fl/+} heterozygote mice and these mice are being bred to homozygosity as well as being crossed to the Probasin-CRE (Pb-CRE) mice to obtain homozygous SOX4 floxed males who are Pb-CRE positive (SOX4^{fl/fl}/Cre+). Recently we obtained one Pb-CRE positive, SOX4^{fl/fl} male mouse as well as Wt littermate controls (Figure 2). To determine reproductive health we placed the

Final Report

SOX4^{fl/fl}/Cre+ and control littermate with Wt female mice that were proven breeders. While the Wt littermate was able to successfully mate with multiple females, the SOX4^{fl/fl}/Cre+ mouse was unable to successfully reproduce with any of four females over the course of a 10 week period. These results are suggestive of a reproductive defect resulting from loss of SOX4 in the prostate. Following the 10 week breeding period SOX4^{fl/fl}/Cre+ and littermate control mice were euthanized and the urogenital organs, including the prostate, bladder, seminal vesicles and testis, as well as control organs such as the liver and thymus were dissected. Tissues were cut in half and one portion snap frozen in liquid nitrogen for future protein or RNA analysis and the second half was formalin fixed, paraffin embedded and sectioned for H&E staining. Visual analysis of the tissue sections revealed little differences in prostate structure between the control and SOX4^{fl/fl}/Cre+ mice (Figure 3A and 3B). There are signs of hypertrophy in the SOX4^{fl/fl}/Cre+ mouse, however, hypertrophy can also be seen in the control mouse (compare Figure 3A and 3B). The SOX4^{fl/fl}/Cre+ mouse was able to produce sperm as expected (Figure 3C and 3D) because the Probasin promoter that drives the Cre production is not expressed in the testis. This data lends further support to the hypothesis that the apparent sterility of the SOX4^{fl/fl}/Cre+ mouse is due to prostate defects, although many aspects of this phenotype have yet to be evaluated. Currently our lab is focused on breeding more SOX4^{fl/fl}/Cre+ male mice. These mice will prove invaluable not only to study the possible reproductive effects of prostate specific loss of SOX4, but also to investigate the expression status of direct SOX4 target genes predicted by our ChIP-chip analysis in an *in vivo* model system.

Key Research Accomplishments:

- Expanded the known SOX4 target genes in the prostate to 282
- Identified 3,600 SOX4 binding sites in the proximal promoter of 3,470 different genes
- Developed a novel PBM k-mer based SOX4 binding site search algorithm in the perl programming language
- Identified biological pathways and processes SOX4 influences
- Significantly advanced the breeding of prostate specific SOX4 knockout mice
- Analysis of the first SOX4 knockout mouse suggests a possible reproductive defect

Reportable Outcomes:

- *Manuscripts:* The research presented in Aim 1 has been published in *Cancer Research* and is available in Appendix III and (11).
- *Abstracts:* The research in Aim 1 was presented as a poster at the 2008 Keystone meeting: Signaling Pathways in Cancer and Development. All abstracts can be found in Appendix II.
 - o **C.D. Scharer**, C.D. McCabe, M.F. Berger, M.L. Bulyk, and C.S. Moreno. Whole Genome ChIP-chip Promoter Analysis Identifies Direct Transcriptional Targets for SOX4 in Prostate Cancer Cells [Abstract]. Signaling Pathways in Cancer and Development, Keystone Symposium, March 24-29, 2008. Keystone, Colorado.
 - o **C.D. Scharer**, C.D. McCabe, M. Ali-Seyed, M.F. Berger, M.L. Bulyk, and C.S. Moreno. Genome-wide Promoter Analysis of the SOX4 Transcriptional Network in Prostate Cancer [Abstract]. GDBBS Student Symposium, September 23, 2008. Emory University, Atlanta GA.

- *Presentations:* All research presented in Aim I was presented annually as an oral lecture as required by my graduate program (Genetics and Molecular Biology).
- *Degrees Obtained:* Through the support of this training grant I have successfully completed and defended a dissertation titled: "Integrating Genomics and Molecular Biology: Identifying Transcriptional Targets for the Prostate Cancer Oncogene SOX4 and Evaluating the Efficacy of Aurora Kinase Inhibition in Chemoresistant-Ovarian Cancer." I received my PhD degree in May of 2009.
- *Database:* All ChIP-chip and expression profiling data has been deposited in the GEO database as required for publication under the Accession number: GEO11915
- *Funding Application:* All research presented in this report was part of a successful NIH Competitive Renewal application, applied for by my Principle Investigator Dr. Carlos Moreno.
- *Training:* As a student of the Genetics and Molecular Biology program I attended research seminars twice weekly and have taken 8 hours of course work comprising two classes: 1- a comprehensive Cancer Biology course, and 2- a introductory Bioinformatics course. My mentor and principle investigator, Dr. Carlos Moreno, has informally instructed me in the Perl Programming language as well as intensive direction in the analysis and data mining of microarray data from various platforms.
- *Employment Opportunities:* Following the completion of my degree I have been accepted to a post-doctoral position at Emory University under the mentorship of Dr. Jeremy Boss. Dr. Boss is a leader in understanding the regulation of chromatin structure and epigenetics in the immune system. I will use my bioinformatics and ChIP experience to pursue a MeDIP-SEQ project in his lab, focused on understanding how genome-wide DNA methylation changes as T-cells differentiate in response to various immune challenges.

Conclusion:

In recent years various labs have utilized expression microarray data mining to identify a handful of SOX4 target genes. For the first time, we identified the SOX4 target genes on a truly global scale. Interestingly, this data has highlighted a previously unknown function of SOX4. The vast array of transcription factor targets suggests SOX4 has a role in modulating other transcriptional programs towards a common goal. *In vivo* experiments presented in Aim 2 will aid our understanding of SOX4's role in prostate development and the consequences of prostate specific ablation of SOX4. Preliminary evidence suggests loss of SOX4 has serious reproductive consequences.

One draw back from our ChIP-chip approach was that our NimbleGen chip only contained proximal promoter sequences. SOX4 has been reported to bind at least one enhancer in T-cells (14) and most likely affects other enhancers in our prostate model. Performing either ChIP-SEQ or ChIP-chip using a whole genome tiling array would lend more insight and truly define a global SOX4 regulatory network. Of particular interest to our lab is SOX4's role in WNT signaling. Our lab will explore the details of SOX4's interaction with β -catenin and how this affects the target genes SOX4 affects.

SOX4 has been shown to be overexpressed in prostate cancer as well as many other types of human cancers such as melanoma, medulloblastomas, glioblastomas and leukemias. Identifying the transcriptional programs SOX4 controls is a first step in elucidating how SOX4 promotes carcinogenesis and evaluating SOX4 as a potential drug target in prostate cancer and other malignancies.

References:

1. Berger, M. F., A. A. Philippakis, A. M. Qureshi, F. S. He, P. W. Estep, 3rd, and M. L. Bulyk. 2006. Compact, universal DNA microarrays to comprehensively determine transcription-factor binding site specificities. *Nat Biotechnol* 24:1429-35.
2. Dickson, B. C., A. M. Mulligan, H. Zhang, G. Lockwood, F. P. O'Malley, S. E. Egan, and M. Reedijk. 2007. High-level JAG1 mRNA and protein predict poor outcome in breast cancer. *Mod Pathol* 20:685-93.
3. Hoser, M., S. L. Baader, M. R. Bosl, A. Ihmer, M. Wegner, and E. Sock. 2007. Prolonged Glial Expression of Sox4 in the CNS Leads to Architectural Cerebellar Defects and Ataxia. *J. Neurosci.* 27:5495-5505.
4. Liu, Z. J., M. Xiao, K. Balint, K. S. Smalley, P. Brafford, R. Qiu, C. C. Pinnix, X. Li, and M. Herlyn. 2006. Notch1 signaling promotes primary melanoma progression by activating mitogen-activated protein kinase/phosphatidylinositol 3-kinase-Akt pathways and up-regulating N-cadherin expression. *Cancer Res* 66:4182-90.
5. Moreno, C. S., C. O. Evans, X. Zhan, M. Okor, D. M. Desiderio, and N. M. Oyesiku. 2005. Novel Molecular Signaling and Classification of Human Clinically Nonfunctional Pituitary Adenomas Identified by Gene Expression Profiling and Proteomic Analyses. *Cancer Res* 65:10214-10222.
6. Nissen-Meyer, L. S., R. Jemtland, V. T. Gautvik, M. E. Pedersen, R. Paro, D. Fortunati, D. D. Pierroz, V. A. Stadelmann, S. Reppe, F. P. Reinholt, A. Del Fattore, N. Rucci, A. Teti, S. Ferrari, and K. M. Gautvik. 2007. Osteopenia, decreased bone formation and impaired osteoblast development in Sox4 heterozygous mice. *J Cell Sci* 120:2785-95.
7. Penzo-Mendez, A., P. Dy, B. Pallavi, and V. Lefebvre. 2007. Generation of mice harboring a Sox4 conditional null allele. *Genesis* 45:776-80.
8. Potzner, M. R., C. Griffel, E. Lutjen-Drecoll, M. R. Bosl, M. Wegner, and E. Sock. 2007. Prolonged Sox4 expression in oligodendrocytes interferes with normal myelination in the central nervous system. *Mol. Cell. Biol.*:MCB.00339-07.
9. Reedijk, M., S. Odorcic, L. Chang, H. Zhang, N. Miller, D. R. McCready, G. Lockwood, and S. E. Egan. 2005. High-level coexpression of JAG1 and NOTCH1 is observed in human breast cancer and is associated with poor overall survival. *Cancer Res* 65:8530-7.
10. Reedijk, M., D. Pinnaduwa, B. C. Dickson, A. M. Mulligan, H. Zhang, S. B. Bull, F. P. O'Malley, S. E. Egan, and I. L. Andrulis. 2007. JAG1 expression is associated with a basal phenotype and recurrence in lymph node-negative breast cancer. *Breast Cancer Res Treat.*
11. Scharer, C. D., C. D. McCabe, M. Ali-Seyed, M. F. Berger, M. L. Bulyk, and C. S. Moreno. 2009. Genome-wide promoter analysis of the SOX4 transcriptional network in prostate cancer cells. *Cancer Res* 69:709-17.
12. Van Limpt, V. A., A. J. Chan, P. G. Van Sluis, H. N. Caron, C. J. Van Noesel, and R. Versteeg. 2003. High delta-like 1 expression in a subset of neuroblastoma cell lines corresponds to a differentiated chromaffin cell type. *Int J Cancer* 105:61-9.
13. Wilson, M. E., K. Y. Yang, A. Kalousova, J. Lau, Y. Kosaka, F. C. Lynn, J. Wang, C. Mrejen, V. Episkopou, H. C. Clevers, and M. S. German. 2005. The HMG Box Transcription Factor Sox4 Contributes to the Development of the Endocrine Pancreas. *Diabetes* 54:3402-9.
14. Wotton, D., R. A. Lake, C. J. Farr, and M. J. Owen. 1995. The high mobility group transcription factor, SOX4, transactivates the human CD2 enhancer. *J Biol Chem* 270:7515-22.
15. Wu, X., J. Wu, J. Huang, W. C. Powell, J. Zhang, R. J. Matusik, F. O. Sangiorgi, R. E. Maxson, H. M. Sucov, and P. Roy-Burman. 2001. Generation of a prostate epithelial cell-specific Cre transgenic mouse model for tissue-specific gene ablation. *Mech Dev* 101:61-9.

Appendix I. Curriculum Vitae

CHRISTOPHER SCHARER

Genetics and Molecular Biology
Graduate School of Arts and Sciences, GDBBS
Emory University
Atlanta, GA 30322
(404)712-2808

Education

Emory University, Atlanta, Georgia

- **Ph.D.** in Biomedical and Biological Sciences,
 - o Program: Genetics and Molecular Biology - May, 2009
 - o Dissertation: “Integrating Genomics and Molecular Biology: Identifying Transcriptional Targets for the Prostate Cancer Oncogene *SOX4* and Evaluating the Efficacy of Aurora Kinase Inhibition in Chemoresistant-Ovarian Cancer.”
 - o Advisor: Dr. Carlos S. Moreno
 - o GPA: 4.0

Emory University, Atlanta, Georgia

- **B.S.** in Biology – May, 2004
 - o GPA: 3.4

Academic Awards and Fellowships

Department of Defense Predoctoral Training Grant in Prostate Cancer Research – 2006 – 2009

GDBBS Student Symposium, 2nd Place Poster Award - 2008

GDBBS Excellence in Teaching Award – 2007

NIH Predoctoral Training Grant – GMB, 2005 - 2006

Thomas Aliberti Scholar/Athlete Award – 2004

Research Experience

Doctoral Research:

Genetics and Molecular Biology, GDBBS, Emory University, Atlanta, Georgia, 2004-2009

(Advisor: Dr. Carlos Moreno - cmoreno@emory.edu)

- Analysis of the transcriptional targets for the oncogenic transcription factor *SOX4* using Chromatin Immunoprecipitation (ChIP), followed by DNA microarray and analysis with computational software developed by our lab.
- Investigation into the role of *SOX4* in prostate cancer formation using both a prostate specific over-expression and knockout mouse model.
- Improve treatment options for recurrent ovarian cancer by investigating whether an Aurora kinase family inhibitor can overcome Paclitaxel resistance in ovarian cancer cell lines.

Undergraduate Research:

Department of Neurology, Emory University School of Medicine, Atlanta, Georgia 2003-2004.

(Advisor: Dr. Enrique Torre – etorre@emory.edu)

- Investigation into localized transcription in neuronal axons grown both in culture and purified from mice.
- Analysis of the function of the chimeric, mutant gene *Wlds* and its role in slow Wallerian degeneration in neurons.

Teaching Experience

Teaching Assistant:

Undergraduate Cancer Biology, Emory University, Spring 2006

(Professor: Dr. Gregg Orloff – gregg.orloff@emory.edu)

- Taught one lecture, assisted in student presentations, writing and grading tests, as well as tutoring students.

Undergraduate Tutoring:

- Served as a mentor and tutor for several undergraduates enrolled in Biology classes at Emory University – 100 hours

Additional Activities and Honors

- **Varsity Soccer**, Emory University – 2000-2003
 - o Captain – 2003
 - o UAA All-Conference Honorable Mention - 2002, 2003
 - o Thomas-Aliberti Scholar/Athlete Award - 2004
- **Sigma Chi**, Beta Chi Chapter
- **USLlive Broadcaster** for the Atlanta Silverbacks – 2007-present

Peer Reviewed Publications

2009. **C.D. Scharer**, C.D. McCabe, M. Ali-Seyed, M.F. Berger, M.L. Bulyk, and C.S. Moreno. Genome-wide Location Analysis of the SOX4 Transcriptional Network in Prostate Cancer. *Cancer Research*, **69**: 709-717.

2009. **C.D. Scharer**, N. Laycock, A.O. Osunkoya, S. Logani, J.F. McDonald, B.B. Benigno, and C.S. Moreno. Aurora kinase inhibitors synergize with paclitaxel to induce apoptosis in ovarian cancer cells. *Journal of Translational Medicine*, **6**: 79

2006. P. Liu, S. Ramachandran, M. Ali-Seyed, **C.D. Scharer**, N. Laycock, W. B. Dalton, H. Williams, S. Karanam, M. W. Datta, D. L. Jaye, and C. S. Moreno. SOX4 is a Transforming Oncogene in Human Prostate Cancer Cells. *Cancer Research*, **66**: 4011-4018.

Published Abstracts

C.D. Scharer, C.D. McCabe, M.F. Berger, M.L. Bulyk, and C.S. Moreno. Whole Genome ChIP-chip Promoter Analysis Identifies Direct Transcriptional Targets for SOX4 in Prostate Cancer Cells [Abstract]. Signaling Pathways in Cancer and Development, Keystone Symposium, March 24-29, 2008.

Final Report

Ali-Seyed, M, **C.D. Scharer**, and C.S. Moreno. SOX4 Participates in an Epidermal Growth Factor Receptor Positive Feedback Loop [Abstract]. Mechanisms & Models of Cancer, Cold Spring Harbor Laboratory, August 16-20, 2006.

Appendix II. Meeting Abstracts**A. Keystone Symposium – Signaling Pathways in Cancer and Development****Whole Genome ChIP-chip Promoter Analysis Identifies Direct Transcriptional Targets for SOX4 in Prostate Cancer Cells**

Christopher D. Scharer^{1,2}, Colleen D. McCabe², Michael F. Berger^{3,4}, Martha L. Bulyk³⁻⁶, and Carlos S. Moreno^{2,7}

¹Graduate Program in Genetics and Molecular Biology, Emory University, Atlanta, GA 30322, ²Department of Pathology & Laboratory Medicine, Emory University School of Medicine, ³Division of Genetics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, ⁴Harvard University Graduate Biophysics Program, Cambridge, MA 02138, ⁵Harvard/MIT Division of Health Sciences and Technology, Harvard Medical School, Boston, MA 02115, ⁶Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, ⁷Winship Cancer Institute, Emory University

In mice, SOX4 is a critical developmental regulator and is required for precise differentiation and proliferation in multiple tissues. SOX4 is upregulated in multiple human tumors including prostate cancer, where SOX4 protein is overexpressed and highly correlated with increasing tumor grade. The exact role of SOX4 in development and promoting tumorigenesis however is currently unknown. Here we sought to identify the direct transcriptional targets of SOX4 on a global scale to determine the gene networks affected in human cancers and development. Using chromatin immunoprecipitation coupled to DNA microarrays tiling the promoters of 25,000 known genes (ChIP-chip), we identified 140 high confidence promoter regions bound by SOX4 in living human prostate cancer cells. We have also used a unique protein-binding double-stranded DNA microarray to determine a novel SOX4 specific position-weight matrix for *in silico* SOX4 binding site searches. Direct targets of SOX4 include several key cellular regulators such as EGFR, ERBB2, DICER, HSP90, PDPK1, and FOXO3. Interestingly, SOX4 also regulates 21 other transcription factors such as SOX11, ZDHHC21, and ZHX2. Through regulation of Delta-like 1 (DLL1) and HES2 SOX4 impacts the Notch pathway, FGF signaling via regulation of FGFR1, as well as the Hedgehog pathway via regulation GLIS2. These data provide new insights into how SOX4 impacts growth factor and developmental signaling pathways and how these changes may influence cancer progression.

B. GDBBS Student Symposium

Genome-wide Promoter Analysis of the *SOX4* Transcriptional Network in Prostate Cancer

Christopher D. Scharer^{1,2}, Colleen D. McCabe², Mohamed Ali-Seyed², Michael F. Berger^{3,4}, Martha L. Bulyk^{3,6} and Carlos S. Moreno^{2,7}

¹Program in Genetics & Molecular Biology, Emory University

²Department of Pathology & Laboratory Medicine, Emory University School of Medicine, Atlanta, GA 30322

³Division of Genetics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115

⁴Committee on Higher Degrees in Biophysics, Harvard University, Cambridge, MA 02138

⁵Harvard/MIT Division of Health Sciences and Technology, Harvard Medical School, Boston, MA 02115

⁶Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115

⁷Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA 30322

ABSTRACT

SOX4 is a critical developmental transcription factor in vertebrates and is required for precise differentiation and proliferation in multiple tissues. In addition, *SOX4* is overexpressed in many human malignancies, but the exact role of *SOX4* in cancer progression is not well understood. Here we have identified the direct transcriptional targets of *SOX4* using a combination of genome-wide localization ChIP-chip analysis and transient overexpression followed by expression profiling in a prostate cancer model cell line. We have also used protein-binding microarrays to derive a novel *SOX4*-specific position-weight matrix and determined that *SOX4* binding sites are enriched in *SOX4*-bound promoter regions. Direct targets of *SOX4* include several key cellular regulators such as *EGFR*, *HSP70*, *Tenascin C*, *Frizzled-5*, *Patched-1*, and *Delta-like 1*. We also show that *SOX4* targets 23 transcription factors such as *MLL*, *FOXA1*, *ZNF281*, and *NKX3-1*. In addition, *SOX4* directly regulates three components of the RNA-induced silencing complex (RISC), namely *Dicer*, *Argonaute 1*, and *RNA Helicase A*. These data provide new insights into how *SOX4* impacts developmental signaling pathways and how these changes may influence cancer progression via regulation of many genes involved in microRNA processing, transcriptional regulation, the *TGF β* , *Wnt*, *Hedgehog*, and *Notch* pathways, growth factor signaling, and tumor metastasis.

Appendix III. Aim 1 Publication: Scharer et al. *Cancer Research*, 69: 709-71

Genome-Wide Promoter Analysis of the *SOX4* Transcriptional Network in Prostate Cancer Cells

Christopher D. Scharer,^{1,2} Colleen D. McCabe,² Mohamed Ali-Sayed,² Michael F. Berger,^{4,7} Martha L. Bulyk,^{4,5,6,7} and Carlos S. Moreno^{2,3}

¹Program in Genetics and Molecular Biology, ²Department of Pathology and Laboratory Medicine, and ³Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia; ⁴Division of Genetics, Department of Medicine and ⁵Department of Pathology, Brigham and Women's Hospital and Harvard Medical School; ⁶Harvard/MIT Division of Health Sciences and Technology, Harvard Medical School, Boston, Massachusetts; and ⁷Committee on Higher Degrees in Biophysics, Harvard University, Cambridge, Massachusetts

Abstract

SOX4 is a critical developmental transcription factor in vertebrates and is required for precise differentiation and proliferation in multiple tissues. In addition, *SOX4* is overexpressed in many human malignancies, but the exact role of *SOX4* in cancer progression is not well understood. Here, we have identified the direct transcriptional targets of *SOX4* using a combination of genome-wide localization chromatin immunoprecipitation–chip analysis and transient overexpression followed by expression profiling in a prostate cancer model cell line. We have also used protein-binding microarrays to derive a novel *SOX4*-specific position-weight matrix and determined that *SOX4* binding sites are enriched in *SOX4*-bound promoter regions. Direct transcriptional targets of *SOX4* include several key cellular regulators, such as *EGFR*, *HSP70*, *Tenascin C*, *Frizzled-5*, *Patched-1*, and *Delta-like 1*. We also show that *SOX4* targets 23 transcription factors, such as *MLL*, *FOXA1*, *ZNF281*, and *NKX3-1*. In addition, *SOX4* directly regulates expression of three components of the RNA-induced silencing complex, namely *Dicer*, *Argonaute 1*, and *RNA Helicase A*. These data provide new insights into how *SOX4* affects developmental signaling pathways and how these changes may influence cancer progression via regulation of gene networks involved in microRNA processing, transcriptional regulation, the *TGFβ*, *Wnt*, *Hedgehog*, and *Notch* pathways, growth factor signaling, and tumor metastasis. [Cancer Res 2009;69(2):709–17]

Introduction

The sex determining region Y-box 4 (*SOX4*) gene is a developmental transcription factor important for progenitor cell development and *Wnt* signaling (1, 2). *SOX4* is a 47-kDa protein that is encoded by a single exon and contains a conserved high-mobility group DNA-binding domain (DBD) related to the *TCF/LEF* family of transcription factors that mediate transcriptional responses to *Wnt* signals. *SOX4* directly interacts with β -catenin, but its precise role in the *Wnt* pathway is unknown (2). In adult mice, *SOX4* is expressed in the gonads, thymus, T-lymphocyte and pro-B-lymphocyte lineages, and to a lesser extent in the lungs,

lymph nodes, and heart (1). Embryonic knockout of *SOX4* is lethal around day E14 due to cardiac failure, and these mice also showed impaired lymphocyte development (3). Tissue-specific knockout of *SOX4* in the pancreas results in failure of normal development of pancreatic islets (4). *SOX4* heterozygous mice have impaired bone development (5), whereas prolonged expression of *SOX4* inhibits correct neuronal differentiation (6). These studies suggest a critical role for *SOX4* in cell fate decisions and differentiation.

Whereas *SOX2* is critical for maintenance of stem cells (7), *SOX4* may specify transit-amplifying progenitor cells that are the immediate daughters of adult stem cells and have been proposed to be the population that gives rise to cancer stem cells. In humans, *SOX4* is expressed in the developing breast and osteoblasts and up-regulated in response to progestins (8). *SOX4* is up-regulated at the mRNA and protein level in prostate cancer cell lines and patient samples, and this up-regulation is correlated with Gleason score or tumor grade (9). In addition, *SOX4* is overexpressed in many other types of human cancers, including leukemias, melanomas, glioblastomas, medulloblastomas (10), and cancers of the bladder (11) and lung (12). A meta-analysis examining the transcriptional profiles of human cancers found *SOX4* to be 1 of 64 genes up-regulated as a general cancer signature (12), suggesting that *SOX4* has a role in many malignancies. Furthermore, *SOX4* cooperates with *Evi1* in mouse models of myeloid leukemogenesis (13). Recently, we showed that *SOX4* can induce anchorage-independent growth in prostate cancer cells (9). Consistent with the concept that *SOX4* is an oncogene, three independent studies searching for oncogenes have found *SOX4* to be one of the most common retroviral integration sites, resulting in increased mRNA (14–16).

Despite these findings, the role that *SOX4* plays in carcinogenesis remains poorly defined. Whereas the transactivational properties of *SOX4* have been characterized (17), genuine transcriptional targets remain elusive. To date, three studies have used expression profiling of cells after either small interfering RNA (siRNA) knockdown or overexpression of *SOX4* to identify candidate downstream target genes (9, 11, 18). Very recently, 31 *SOX4* target genes were confirmed by chromatin immunoprecipitation (ChIP) in a hepatocellular carcinoma cell line (19). Although interesting, this study was limited by the fact that it focused on a specific tumor stage transition and did not use a genome-wide localization approach.

Here, we have performed a genome-wide localization analysis using a ChIP-chip approach to identify those genes that have *SOX4* bound at their proximal promoters in human prostate cancer cells. We have identified 282 genes that are high-confidence direct *SOX4* targets, including many genes involved in microRNA (miRNA) processing, transcriptional regulation, developmental pathways, growth factor signaling, and tumor metastasis. We have also used

Note: Supplementary data for this article are available at Cancer Research Online (<http://cancerres.aacrjournals.org/>).

Requests for reprints: Carlos S. Moreno, Department of Pathology and Laboratory Medicine, Winship Cancer Institute, Emory University, Whitehead Research Building, Room 105J, 615 Michael Street, Atlanta, GA 30322. Phone: 404-712-2809; Fax: 404-727-8538; E-mail: cmoreno@emory.edu.

©2009 American Association for Cancer Research.

doi:10.1158/0008-5472.CAN-08-3415

unique protein-binding DNA microarrays (PBM; refs. 20–22) to query the binding of recombinant SOX4 to every possible 8-mer. The PBM-derived *SOX4* DNA binding data will further facilitate computational analyses of genomic *SOX4* binding sites. These data provide new insights into how *SOX4* affects key growth factor and developmental pathways and how these changes may influence cancer progression.

Materials and Methods

Cell culture and stable cell line construction. All cell lines were cultured, as described by American Type Culture Collection except LNCaP cells, which were cultured with T-Medium (Invitrogen). HA-tagged *SOX4* was cloned into the pHR-UBQ-IRES-eYFP-ΔU3 lentiviral vector (gift from Dr. Hihn Ly, Emory University), and stable cells were isolated, as previously described (23).

ChIP. Two 90% confluent P150s of both LNCaP-YFP and LNCaP-YFP/HA-SOX4 or RWPE-1-YFP and RWPE-1-YFP/HA-SOX4 cells were formaldehyde fixed and sonicated, and ChIP assay was performed, as described previously (23). Anti-HA 12CA5 or mouse IgG was used to immunoprecipitate protein-DNA complexes overnight at 4°C and collected using Dynal M280 sheep anti-mouse IgG beads for 2 h. Dynal beads were washed, protein-DNA complexes were eluted, and DNA was purified, as described previously (24). A detailed description of the ChIP-chip protocol can be found in Supplementary Methods. Anti-HA 12CA5, anti-Flag-M2 (Sigma-Aldrich), or mouse IgG was used to immunoprecipitate protein-DNA complexes overnight at 4°C. All PCR primers used in ChIP-PCR can be found in Supplementary Table S7.

ChIP-chip analysis. To determine the direct *SOX4* target genes on a global scale, we performed ChIP assays in triplicate from the LNCaP cell line stably expressing *SOX4* and in duplicate from a control cell line that expressed YFP alone. Immunoprecipitated and input DNA were subjected to whole genome amplification, Cy3/Cy5 fluorescent labeling, and

hybridization to the NimbleGen 25K human promoter array set. Input and immunoprecipitated DNA isolated from LNCaP-YFP and LNCaP-YFP/HA-SOX4 cells were amplified using linker-mediated PCR as described previously (25). Amplified DNA was labeled and hybridized in triplicate by NimbleGen Systems, Inc., to their human 25K promoter array. This set consists of two microarrays that tile 4 kb of upstream promoter sequence and 750 bp of downstream intronic sequence on average, with a total genomic coverage of 110 Mb. Raw hybridization data were Z-score normalized, and ratios of immunoprecipitation to input DNA were determined for each sample. ChIPOTle software was used to determine enriched peaks using a 500-bp sliding window every 50 bp, as previously described (23). NimbleGen microarray data are available from the GEO database accession number GEO11915.

Luciferase assays. PCR fragments representing the binding sites in the *EGFR*, *ERBB2*, and *TLE1* genes were cloned in front of the pGL3-promoter luciferase construct (Promega). Primers sequences used can be found in Supplementary Table S7. LNCaP cells were transfected with 100 ng of TK-*Renilla* construct, 500 ng of pGL3-promoter vector alone and with cloned inserts, and 500 ng of either a *SOX4* or vector expression construct. Dual luciferase assays were performed 48 h posttransfection, according to the manufacturer's guidelines (Promega). All assays were performed in triplicate on separate days.

Quantitative real-time PCR. LNCaP cells were plated in six-well culture dishes and grown to 90% confluency before transfection with 1 μg of *SOX4* plasmid or vector control using Lipofectamine 2000 (Invitrogen). At 24 h posttransfection, total RNA was harvested using the RNeasy kit (Qiagen), and reverse transcription was performed using Superscript III reverse transcriptase (Invitrogen). Quantitative real-time PCR (qPCR) was performed using SYBR Green I (Invitrogen) on a Bio-Rad iCycler using 18s or β-actin as a control, and data were analyzed using the δCt method (26). All primers used in this study are listed in Supplementary Table S7.

Microarray analysis. Total RNA was isolated from three independent experiments of either vector control or *SOX4*-transfected LNCaP cells, as





Figure 1. A, Affymetrix U133A GeneChip microarray analysis of *SOX4* overexpression and knockdown in LNCaP prostate cancer cells. Overexpression of *SOX4* leads to increased *EGFR* expression, whereas siRNA knockdown of *SOX4* results in decreased *EGFR* expression. B, schematic showing the location of the *SOX4* binding site in the first intron of the *EGFR* (top) and *ERBB2* (bottom) genes. Arrows denote location of the *SOX4* binding site. C, ChIP assay of FLAG-SOX4 bound to the introns of *EGFR*, *ERBB2*, and *TLE1*. *PSMA* is shown as a negative control. *SOX4* bound DNA is specifically amplified in the FLAG immunoprecipitation lane from FLAG-SOX4 expressing cells (lane 3) and not control cells (lane 5) or with a nonspecific antibody (lanes 2 and 4). D, luciferase reporter assays with *SOX4* binding sites showing activation in the presence of *SOX4* compared with empty vector. *, $P < 0.01$ by Student's t test; bars, SD ($n = 3$ independent biological replicates performed on separate days).

Figure 2. A, graph showing enrichment in the three HA-SOX4 lanes over the average of the two YFP replicates for the *SOX4* target gene *FMO4*. Y axis is the signal intensity across the genomic coordinates on the X axis. B, qPCR ChIP analysis of 10 randomly selected genes verified in both the RWPE-1 and LNCaP cell lines. Graph shows fold enrichment of the HA-SOX4 immunoprecipitation over the YFP negative control immunoprecipitation. Numbers above the bars represent the mean log₂ of fold enrichment of ChIP-chip signal for the probes contained in the peak relative to YFP. Bars, SD ($n = 3$ technical replicates). C and D, genes that were verified by conventional ChIP assay. HA-SOX4 and YFP cells were subjected to conventional ChIP followed by PCR in both the LNCaP (C) and RWPE-1 (D) prostate cell lines. Six genes verified in the LNCaP cell lines and five in the RWPE-1 cell lines.



described above. Each transfection was performed in triplicate, and each sample was hybridized in duplicate, creating six data points for each condition. Total RNA was submitted to the Winship Cancer Institute DNA Microarray Core facility.⁸ All samples showed RNA integrity of 8.3 or greater using an Agilent 2100 Bioanalyzer. RNA was hybridized to the Illumina Human6 v2 Expression Beadchip that query roughly 47,000 transcripts with 48,701 probes, and after normalization, significantly changed probes were calculated using significance analysis of microarrays (SAM) software (27). Settings for SAM were two-class unpaired ($\times 4$ versus vector control) imputation engine (10 nearest neighbor), permutations (500), RNG seed (1234567), Delta (1.316), fold change (1.5), and false discovery rate (0.749%). Microarray data are available in the GEO database accession number GEO11915.

Immunoblotting. Cells were lysed in lysis buffer [0.137 mol/L NaCl, 0.02 mol/L TRIS (pH 8.0), 10% glycerol, and 1% NP40], and 50 μ g total lysate were separated by SDS-PAGE electrophoresis and transferred to nitrocellulose for immunoblotting. Immunoblots were probed with polyclonal rabbit *SOX4* antisera described previously (9) and *DICER* (Santa Cruz). To control for

equal loading, immunoblots were also probed with a mouse monoclonal antibody to protein phosphatase 2A (*PP2A*) catalytic subunit (BD Biosciences).

Results

SOX4 transcriptionally activates *EGFR*. Using expression profiling to determine the genes whose mRNA levels change when *SOX4* is either overexpressed or eliminated using siRNA (9), we identified *EGFR* as a candidate *SOX4* transcriptional target (Fig. 1A). Analysis of the promoter and first intron of *EGFR* and other family members with CONFAC software (28) revealed the presence of potential *SOX4* binding sites within the first intron of *EGFR* and *ERBB2* (Fig. 1B). CONFAC functions by identifying the conserved sequences in the 3-kb proximal promoter region and first intron of human-mouse orthologue gene pairs and then identifying transcription factor binding sites (TFBS), defined by position weight matrices from the MATCH software (29), which are conserved between the two species (28).


Whereas limited commercial antibodies exist for *SOX4* and show activity in immunoblots, in our hands, none of them have been

⁸ <http://microarray.cancer.emory.edu/>

useful in a ChIP assay. Therefore, we used epitope-tagged *SOX4*, as described in other *SOX4* ChIP studies (9, 19). Although the FLAG epitope tag was not tested directly for activity, a glutathione *S*-transferase (GST)-*SOX4* construct showed binding to a known *SOX4* motif and not a control motif (Supplementary Fig. S2B), validating that the epitope tag does not interfere with *SOX4* binding. To determine if *SOX4* directly bound the *EGFR* and *ERBB2* enhancers, we performed ChIP analysis on RWPE-1 prostate cancer cells stably infected with FLAG-*SOX4* or a control lentiviral vector. DNA representing the predicted *SOX4* sites was specifically amplified from the FLAG-*SOX4* cell line and not from the control cell line, indicating that *SOX4* binds to intronic sequence of *EGFR* and *ERBB2* (Fig. 1C). *EGFR* is expressed in RWPE-1 cells, but not in LNCaP cells, and *SOX4* did not bind to these sequences in LNCaP cells (data not shown).

To characterize the transcriptional effect of *SOX4* levels on the regions bound by *SOX4* in ChIP assays, the amplified ChIP fragments were cloned in front of a minimal promoter luciferase reporter plasmid and tested in transient transfections in LNCaP cells. Compared with a vector control, *SOX4* significantly increased transcription of the *EGFR* fragment 3-fold and the *TLE1*-positive control fragment roughly 4-fold. Although not found significant, *ERBB2* was activated 1.5-fold compared with the vector control (Fig. 1D). Consistent with microarray data, *SOX4* transcriptionally activates the *EGFR* enhancer.

Genome-wide localization analysis. To determine the direct *SOX4* target genes on a global scale, we performed ChIP assays in triplicate from the LNCaP HA-*SOX4* stable cell line and in duplicate from the control LNCaP-YFP cell line. Peaks ($P < 0.001$) that overlapped in at least two of the three data sets and were not



present in the LNCaP-YFP cell line were called significant (Fig. 2A). Based on these variables, we classified 3,600 significant, overlapping peaks as *SOX4* target sequences. Because some transcription start sites (TSS) are quite close to each other (<3 kb), it was not always possible to assign a unique gene to every peak. In addition, many genes had multiple peaks in their promoters, and thus, we mapped the 3,600 peaks to 3,470 different genes (Supplementary Table S1).

To verify the set of 3,600 *SOX4* peaks, 28 candidate *SOX4* target sites representing a range of *P* values in promoters of genes of biological interest were chosen, primers were designed around the peaks and enrichment was verified by conventional ChIP. Ten of these 28 candidates were analyzed by ChIP qPCR and 18 by ChIP-PCR. Overall, 24 of 28 (86%) of the candidate targets were confirmed, validating our data set. All 10 of the peaks chosen to validate by qPCR were reproducibly enriched over the *YFP* control in both the LNCaP-HA-SOX4 cell line and the RWPE-1 cell line (Fig. 2B). Of the target sites validated by conventional PCR, 14 of 18 genes were confirmed in both the LNCaP and RWPE-1 cell lines, whereas a mock, control PCR was negative (Fig. 2C and D; data not shown). The only exception was *ANKRD15*, which was enriched only in the LNCaP cell line and not in the RWPE-1 line.

Target gene expression analysis. To determine whether *SOX4* binding affects transcription of the 3,470 genes that have *SOX4* bound at their promoters, we performed whole genome expression analysis on LNCaP cells after transfection with *SOX4* or a control vector. To increase the likelihood of identifying direct *SOX4* targets, total RNA was isolated at a relatively early time point (24 hours posttransfection) and hybridized to Illumina Human 6-v2 whole genome arrays. A total of 1,766 genes were changed at least 1.5-fold with a false discovery rate of 0.749% (Fig. 3A; Supplementary Table S2). Of those 1,766 genes, 244 were also direct *SOX4* targets by ChIP-chip analysis (Fig. 3A; Supplementary Table S3). Seven of these genes were confirmed by qPCR (Fig. 3B).

Our previous expression profiling of LNCaP cells after *SOX4* siRNA knockdown (9) identified 465 downstream targets, and we confirmed that *SOX4* regulates the expression of *DICER*, *DLL1*, and *HES2* in LNCaP cells by qPCR (Fig. 3B). We further confirmed *SOX4* regulation of *DICER* at the protein level (Fig. 3C). Out of those 465 candidate targets, 47 genes overlapped with the 3,470 ChIP-chip targets, increasing the number of direct *SOX4* targets to 282 genes (Fig. 3A; Supplementary Table S3). We classified these 282 genes bound by *SOX4* in ChIP-chip and significantly changed by expression profiling as high confidence direct *SOX4* target genes. Nine genes (*PIK4CA*, *DHX9*, *BTN3A3*, *CDK2*, *MVK*, *ADAM10*, *RYK*, *ISG20*, and *DBI*) overlapped in all three data sets. The transcription factor *SON* and purine biosynthetic enzyme *GART*, two genes on chromosome 21 that are transcribed in opposite directions and regulated by a bidirectional promoter, were affected in opposite ways. *SON* was activated by *SOX4* 1.8-fold, as detected by *SOX4* overexpression, whereas *GART* was increased almost 3-fold as determined by *SOX4* siRNA knockdown, suggesting that *SOX4* regulates the directionality of this promoter.

We next analyzed the *P* values of the peaks in our ChIP-chip data set, comparing the *P* values of the genes that were altered by transient overexpression of *SOX4* with those that were not (Supplementary Fig. S2). We found no difference in the distributions of the ChIP-chip *P* values for those genes that were changed in expression profiling experiments and those that were not. Thus, based on our ChIP-chip validation experiments and the similar *P*-value distributions, we conclude that *SOX4* is genuinely bound at

the promoters of the 3,188 genes that did not change but that *SOX4* by itself is not limiting or sufficient to generate changes in transcription without corresponding changes in the cellular context, such as activation of cofactors or signaling pathways.

Novel *SOX4* position weight matrix. To facilitate computational analyses of *SOX4* DNA binding sites, we sought to determine the DNA binding preferences of *SOX4* using universal PBMs (20). This universal PBM array allows recombinant *SOX4* protein to interact with and bind every possible 8-mer, thus allowing *in vitro* binding site specificities to be calculated.

We generated an NH₂ terminal, GST-SOX4-DBD fusion protein, expressed and purified it from *E. coli*, and tested for activity (Supplementary Fig. S3). The GST-SOX4-DBD was incubated with the protein binding microarray and a novel position weight matrix (PWM; RWYAAWRV) was calculated from the PBM data (Supplementary Table S4) using the Seed-and-Wobble algorithm (Fig. 3D; ref. 20). Three groups have previously reported similar binding site sequences for *SOX4*: AACAAAG (30), AACAAAT (31), and WWCAAWG (19). Our PWM confirms the *SOX4* core binding sequence of the previously known binding sites but there are some differences in the specificity at the 1st and 7th positions and we find a bias toward A, C, and G at the 8th position. These differences could be due to the fact that earlier reports used no more than 31 sequences to develop the binding motif, whereas our study queried every possible 8-mer.

***SOX4* peaks contain *SOX4* binding sites.** Using our newly derived PWM, we applied CONFAC software (28) to analyze the enriched sequences for the presence of *SOX4* binding sites. We analyzed the sequences of the peaks in the promoters of our 282 high confidence genes against 10 sets of control promoter sequences to see if *SOX4* sites were enriched in our target gene set. Control promoter peaks of equal size to *SOX4* peaks were chosen randomly from sequences covered by the NimbleGen array, and each control set contained equal total sequence coverage as our 282 high confidence peaks. With stringent criteria (core similarity, >0.85; matrix similarity, >0.75), we find that 60% of the peaks contain *SOX4* binding sites. *SOX4* sites were significantly enriched relative to 10 sets of random promoter sequence by Mann-Whitney *U* test using Benjamini correction for multiple hypothesis testing ($q < 0.0019$).

To further characterize the *SOX4* binding sites, we searched the entire set of 3,600 *SOX4* peaks and 10 equal sets of random promoter sequence for the presence of PBM-bound k-mers (here, ungapped 8-mers). The specificity of PBM k-mers can be quantified by the enrichment score (ES), which ranges from -0.5 to 0.5 (32). We analyzed the enrichment of PBM k-mers with $0.45 > \text{ES} > 0.40$ (moderate) and $\text{ES} > 0.45$ (stringent). Whereas both *SOX4*-bound peaks and random promoter sequence contained moderate and stringent k-mers, *SOX4* peaks contained significantly more stringent ($P = 0.0002$) and moderate ($P = 1.08 \times 10^{-5}$) k-mers by two-tailed Mann-Whitney test (Supplementary Fig. S4).

To investigate interaction with protein partners that may increase *SOX4* affinity for poor matching sites *in vivo*, we searched for enrichment of cooccurring TFBS in the *SOX4* peaks. We applied CONFAC software to search the sequences for the presence of co-occurring transcription factor binding sites within the same peak (Table 1). Using the same criteria as above, we determined that the *E2F* family had the most frequently co-occurring motif (similar to TTTCGCGC, $q = 1.78 \times 10^{-11}$). Interestingly, ingenuity pathway analysis (IPA) identified cell cycle as a functionally enriched process in the 3,470 *SOX4* target genes ($P = 0.00916$), suggesting

Table 1. Benjamini corrected q values for co-occurring transcription factor binding sites

Transcription factor	Family	Benjamini corrected q value
E2F4	E2F	1.78E-11
E2F1	E2F	3.06E-11
PAX5	Paired box	2.07E-10
WHN	Forkhead	2.94E-10
SMAD3	SMAD	1.82E-09
SMAD4	SMAD	3.33E-09
MYC	MYC	6.25E-09
NFKAPPAB	NF- κ B	2.95E-08
LEF1/TCF1	LEF	1.12E-06

that part of *SOX4*'s function is to control the expression of genes involved in cell cycle progression.

CONFAC analysis identified other significant TFBS motifs enriched in the *SOX4* peaks (Table 1), including those for transcription factors in the *TGF β* , *Wnt*, and *NF- κ B* pathways. *SOX4* modulates *Wnt* signaling via interaction with β -catenin and the *TCF4* transcription factor (2), suggesting a possible role for *SOX4* in transcriptionally modulating *Wnt* signals. We confirmed the recent report that *SOX4* cooperates with constitutively active β -catenin to activate TOP-Flash luciferase reporters (2) and found that *SOX4* synergistically induces activation of these constructs, further highlighting a role for *SOX4* in the *Wnt* pathway (Supplementary Fig. S5).

***SOX4* target genes.** To determine the biological processes and functions of the *SOX4* targets, we performed a gene ontology analysis using DAVID software (33) on the 282 high confidence *SOX4* targets. Among the *SOX4* targets were 23 transcription factors (Table 2), and DAVID analysis determined that the top annotations were transcription ($P = 3.7 \times 10^{-18}$), transmembrane ($P = 5.59 \times 10^{-10}$), and protein phosphorylation/dephosphorylation ($P = 3.5 \times 10^{-18}/6.6 \times 10^{-7}$). These findings are paralleled by expression profiling of *SOX4* overexpression in HU609 bladder carcinoma cells where top annotated functions were signal transduction and protein phosphorylation (11).

Commercial IPA software⁹ identified biological pathways and functions that are enriched in our 282 high confidence targets, 1,766 significant genes identified by SAM analysis, and the 3,470 unique genes that had *SOX4* bound at their promoters in ChIP-chip. As anticipated, among the most significant annotations were cell cycle, cancer, and tissue development. In the significant expression data set of 1,766 genes, we observed an up-regulation of three Frizzled family receptors, *FZD3*, *FZD5*, and *FZD8*, as well as the downstream transcription factor *TCF3*. Overall, IPA analyses discovered key components of the *EGFR*, *Notch*, *AKT-PI3K*, miRNA, and *Wnt- β -catenin* pathways as *SOX4* regulatory targets. Based on these findings, we built *SOX4* regulatory networks found in prostate cancer cells (Fig. 4 and Supplementary Fig. S6). *SOX4* target genes comprise key pathway components, such as ligands (*DLL1* and *NGR1*), receptors (*FZD5* and *PTCH1*), an AKT regulatory kinase (*PDPK1*), and downstream transcription factors (*FOXO3* and *HES2*). In addition, *SOX4* activates expression of

tenascin C, an extracellular matrix protein that is a target of *TGF β* signaling (34) and β -catenin (35). In addition, *SOX4* regulates three components of the RNA-induced silencing complex (RISC) complex, *DICER*, *Argonaute 1* (*AGO1*), and *RHA/DHX9* (Supplementary Table S3). We confirmed these data by qPCR (Fig. 3B) and Western blot for *DICER* (Fig. 3C).

Gene set enrichment analysis (GSEA; ref. 36) and GSEA leading edge analysis (37) of these gene sets identified *TGF β* -induced *SMAD3* direct target genes (Supplementary Table S5) as enriched in *SOX4* target genes. *SOX4* is up-regulated by *TGF β -1* treatment (4, 38), and we found *SMAD4* sites are significantly enriched in the *SOX4* ChIP-chip peaks (Table 1), suggesting that *SOX4* affects key developmental and growth factor signaling pathways in prostate cancer cells at both the transmembrane signaling and transcriptional levels.

Discussion

Whereas many studies have identified *SOX4* as a crucial developmental transcription factor that is often overexpressed in many types of malignancies, little is known of what *SOX4* regulates in cancer cells. We have used a ChIP-chip approach to report the first genome-wide localization analysis of *SOX4* and mapped 3,600 binding peaks that represent 3,470 unique genes possibly under the transcriptional control of *SOX4*. We have also identified 1,766 genes that respond to increased *SOX4* levels by whole genome expression profiling. Integration of these data sets mapped 282 high-confidence direct targets in the *SOX4* transcriptional network. In addition, we have used protein-binding microarrays

Table 2. DAVID analysis identified 23 transcription factors present in our high confidence *SOX4* target genes

Entrez ID	Symbol	Microarray fold change
196528	ARID2	1.99
2001	ELF5	-2.65
3169	FOXA1	-2.47
2976	GTF3C2	-3.12
64412	GZF1	2.42
84458	LCOR	2.41
4173	MCM4	1.55
58508	MLL3	2.06
10933	MORF4L1	2.07
8031	NCOA4	2.64
4784	NFIX	-2.83
4824	NKX3-1	-4.53
7799	PRDM2	2.48
5933	RBL1	1.80
55509	SNFT	-2.32
6722	SRF	-2.03
54816	SUHW4	-1.93
9412	SURB7	-2.24
9338	TCEAL1	-1.57
7718	ZNF165	1.53
7738	ZNF184	1.66
23528	ZNF281	1.71
30834	ZNRD1	-1.63

NOTE: Gene ontology term: transcription, DNA dependent ($P = 3.7 \times 10^{-18}$).

⁹ <http://www.ingenuity.com>




Figure 4. IPA analysis of direct target genes graphically illustrating the cellular location of the *SOX4* transcriptional target genes. *SOX4* regulates a host of nuclear and membrane localized proteins, as well as multiple components of the RISC complex. Red, target genes up-regulated by *SOX4*; green, down-regulated genes; white, genes for which no expression change was detected.

to determine a novel PWM specific for *SOX4* and show that our ChIP-chip predicted peaks are significantly enriched for *SOX4* binding sites. These data provide several new insights into the roles that *SOX4* plays in the cell.

***SOX4* direct target genes.** Although only 10% of the significant differentially expressed genes overlapped with the ChIP-chip data, this is likely a conservative estimate because the NimbleGen 25K promoter array only queries proximal promoter sequences and not more than 1 kb downstream of the TSS. We found that *SOX4* binds *EGFR* and *ERBB2* in the first intron over 20 kb downstream of the TSS (Fig. 1D), and unsurprisingly, we did not detect *EGFR* or *ERBB2* in our ChIP-chip experiment. Thus, more of the 1,900 genes that responded to changes in *SOX4* mRNA levels (but were not detected by ChIP-chip) could still be direct targets. Excellent candidates would be the 40 genes that responded to *SOX4* on both microarray platforms, such as the *IL6* receptor, *SOX12*, and *NME1* (Supplementary Table S6). Whereas 3,600 is a fairly large number of *SOX4* bound regions, some background can be expected. Nevertheless, we were able to validate 24 of 28 (86%) candidate binding sites chosen, adding confidence to our data set. In fact, an even higher number of over 4,200 genomic binding sites had been previously observed for *c-Myc* in ChIP-positron emission tomography whole genome studies (39). Whole genome tiling arrays or

ChIP-seq could provide additional binding sites that may show more overlap with the Illumina expression data set.

Conversely, many of the bound genes may not respond to changes in *SOX4* mRNA levels alone but to multiprotein activator complexes of which *SOX4* is only one component. Furthermore, the stability of *SOX4* bound to a promoter could be greater than unbound *SOX4*, limiting the effects observed by siRNA knockdown. In different cell types or cellular contexts, *SOX4* may activate a different subset of these genes. Of the 31 *SOX4* target genes reported by Liao and colleagues (19), only six are represented in our NimbleGen data set and three found to be changed in our Illumina expression profiling data set. The small overlap could be due to the fact that those genes were identified in hepatocellular carcinomas, whereas we have examined prostate cancer cells. Interestingly, *DKK* was one of the six genes that overlapped in both data sets, further implicating *SOX4* in the *Wnt* pathway. Because *SOX4* is known to interact with β -catenin and other coactivators, it may be poised at many of these promoters to enable responses to developmental signals from the *Wnt* or *TGF β* pathway.

Receptor and signaling regulation. Our data suggest that *SOX4* regulates cellular differentiation through a variety of transcription factors and receptors. *SOX4* is up-regulated in response to numerous external ligands ranging from *TGF β* (38)

and *BMP-6* (40) to parathyroid hormone and progesterone (8). Previous work has shown that *SOX4* directly signals from *IL-5R α* (41), and here, we have shown that *SOX4* directly regulates *EGFR* (Fig. 1). Membrane receptors in the *SOX4* transcriptional network also include Frizzled family members *FZD3*, *FZD5*, *FZD8*; the Hedgehog receptor *PTCH-1*; the Notch ligand *DLL1*; TRAIL decoy receptor *TNFRSF10D*; and other growth factor receptors, such as *FGFRL1* and *IGF2R*. DAVID analysis also revealed protein phosphorylation/dephosphorylation ($P = 3.5 \times 10^{-18}/6.6 \times 10^{-7}$) and transcription ($P = 3.7 \times 10^{-18}$) are enriched annotations, identifying 23 transcription factors that are direct targets of *SOX4*. This evidence suggests that *SOX4* regulates signaling events both at the external input level and the internal output or transcription level. This regulation could be direct, as with *IL-5R α* , or through the transcriptional targets *SOX4* activates.

Transcription factors and *SOX4*. Here, we have reported DNA binding specificity data for *SOX4*, which will improve computational analyses for *SOX4* specific binding sites. Our data confirm the known SOX family core-binding motif and add new specificity at the 1st, 7th, and 8th positions. Whereas crystal structure evidence from *SOX2* has shown the importance of the core-binding motif, it is possible that the specificity for *SOX4* is enhanced outside of the core motif at the extra positions. A limitation of these data is that we did not assess how other DNA binding proteins influence the sequences to which *SOX4* can bind. The enrichment of *SMAD4* sites is particularly interesting in light of the GSEA results, which suggest that *SOX4* regulates many *TGF β* target genes, including *Tenascin C*. Thus, we hypothesize that *SOX4* may physically interact with *SMAD4* in response to *TGF β* signals. Experiments to test this hypothesis are under way. Nevertheless, evidence points to a role for *SOX4* in modulating other transcriptional programs via hierarchical regulation of 23 downstream transcription factors.

***SOX4* and cancer.** Based on the target genes we identified, *SOX4* seems to influence cancer progression in several ways. First, it plays a key role in the activation of and response to developmental pathways, such as *Wnt*, *Notch*, *Hedgehog*, and *TGF β* . Second, *SOX4* inhibits differentiation via repression of transcription factors, such as *NKX3.1*, and activation of *MLL* and *MLL3*, two histone H3 K4 methyltransferases that induce activation of *HOX* gene expression (42). *MLL* methyltransferase complexes also facilitate *E2F* activation of S-phase promoters, facilitating cell cycle progression. Activation of *MLL* also suggests a mechanism for the role of *SOX4* in myeloid leukemogenesis, because *MLL* is a critical oncogene that is often translocated or amplified in this disease (43). Thirdly, *SOX4* targets growth factor receptors, such as *EGFR*, *FGFRL1*, and *IGF2R*, enhancing proliferative signals in tumors and potentially activating the *PI3K-AKT* pathway. Mice heterozygous for *NKX3.1* and *PTEN* in the prostate develop prostate adenocarcinomas and metastases to the lymph node (44). Thus, our data suggest that *SOX4* may promote prostate cancer progression directly through *NKX3.1* repression and indirectly through *PI3K-AKT* activation. Finally, *SOX4* seems to promote metastasis via up-regulation of *tenascin C*. Recently, both *SOX4* and *tenascin C* were shown to enhance metastasis of breast

cancer cells to the lung (45), as has the *TGF β* pathway, which activates their expression (46). Other metastasis-associated *SOX4* target genes include *integrin α_V* and *Rac1*. *Rac1* was recently shown to control nuclear localization of β -catenin in response to *Wnt* signals (47).

***SOX4* regulates components of the RISC complex and small RNA pathway.** miRNAs are small noncoding RNA species that regulate the translation and stability of mRNA messages for hundreds of downstream target genes via partial complementarity to short sequences in the 3' untranslated regions of mRNAs. The RISC, which is composed of AGO1 or AGO2, TRBP, and Dicer processes miRNAs from precursors (pre-miRNA) to their mature form, cleaves target mRNAs, and participates in translational inhibition. *RNA Helicase A (RHA/DHX9)* interacts with the RISC complex and participates in loading of small RNAs into the RISC complex (48). We observed that three components of the RISC complex, *DICER*, *AGO1*, and *RHA/DHX9*, are high-confidence direct targets of *SOX4* (Supplementary Table S3), and we confirmed these data by qPCR (Fig. 3B). *Dicer* has been independently observed to be overexpressed in prostate cancers (49).

In addition, we observed that *Toll-like receptor 3 (TLR3)*, which binds to double-stranded RNAs, induces gene silencing, and can induce apoptosis (50), was induced 2.8-fold upon overexpression of *SOX4*. This induction may be indirect because *TLR3* was not detected by ChIP-chip, but we cannot exclude the possibility that *SOX4* may directly regulate *TLR3* from a distal or intronic enhancer.

Our observation that *SOX4* targets three genes important in small RNA processing is of particular interest in light of the role of *SOX4* in development and cancer progression. miRNAs have been implicated in numerous physiologic processes from development to oncogenesis. miRNAs can also act as suppressors of breast cancer metastasis via targeting of *tenascin C* and *SOX4* (45) and as promoters of breast cancer metastasis (51). The finding that *SOX4* can affect expression of multiple components of the RISC complex also provides insight into why long-term loss of *SOX4* induces widespread apoptosis (9, 18). In summary, these data shed light on the mechanisms and pathways through which *SOX4* may exert its effects during development and cancer progression. Further studies are necessary to elucidate the precise role of *SOX4* in the functioning of these pathways.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Acknowledgments

Received 9/3/2008; revised 10/8/2008; accepted 11/3/2008.

Grant support: National Cancer Institute R01 CA106826 (C.S. Moreno), NIH/NHGRI grant R01 HG003985 (M.F. Berger and M.L. Bulyk), DOD CDMRP Prostate Cancer Predoctoral Training Fellowship PC060145 (C.D. Schärer), and Postdoctoral Training Fellowship PC060114 (C.D. McCabe).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

We thank Dr. Maja Ordanic-Kodani at Winship Cancer Institute Microarray Core Facility for performing Illumina microarray labeling and hybridization, Robert Karaffa at the Emory University FlowCore for cell sorting, Dr. Hinh Ly for IRES-eYFP lentiviral vector, and Dr. Anita Corbett for pGEX-4T-1 plasmid.

References

1. Busslinger M. Transcriptional control of early B cell development. *Annu Rev Immunol* 2004;22:55–79.
2. Sinner D, Kordich JJ, Spence JR, et al. Sox17 and Sox4 differentially regulate β -catenin/T-cell factor activity and proliferation of colon carcinoma cells. *Mol Cell Biol* 2007;27:7802–15.
3. Ya J, Schilham MW, de Boer PA, Moorman AF, Clevers H, Lamers WH. Sox4-deficiency syndrome in mice is an animal model for common trunk. *Circ Res* 1998;83:986–94.

4. Wilson ME, Yang KY, Kalousova A, et al. The HMG box transcription factor Sox4 contributes to the development of the endocrine pancreas. *Diabetes* 2005;54:3402–9.
5. Nissen-Meyer LS, Jemtland R, Gautvik VT, et al. Osteopenia, decreased bone formation and impaired osteoblast development in Sox4 heterozygous mice. *J Cell Sci* 2007;120:2785–95.
6. Hoser M, Baader SL, Bosl MR, Ihmer A, Wegner M, Sock E. Prolonged glial expression of Sox4 in the CNS leads to architectural cerebellar defects and ataxia. *J Neurosci* 2007;27:5495–505.
7. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. *Cell* 2006;126:663–76.
8. Graham JD, Hunt SM, Tran N, Clarke CL. Regulation of the expression and activity by progesterins of a member of the SOX gene family of transcriptional modulators. *J Mol Endocrinol* 1999;22:295–304.
9. Liu P, Ramachandran S, Ali-Sayed M, et al. Sex-determining region Y box 4 is a transforming oncogene in human prostate cancer cells. *Cancer Res* 2006;66:4011–9.
10. Lee CJ, Appleby VJ, Orme AT, Chan WI, Scotting PJ. Differential expression of SOX4 and SOX11 in medulloblastoma. *J Neurooncol* 2002;57:201–14.
11. Aaboe M, Birkenkamp-Demtroder K, Wiuf C, et al. SOX4 expression in bladder carcinoma: clinical aspects and *in vitro* functional characterization. *Cancer Res* 2006;66:3434–42.
12. Rhodes DR, Yu J, Shanker K, et al. Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression. *Proc Natl Acad Sci U S A* 2004;101:9309–14.
13. Boyd KE, Xiao YY, Fan K, et al. Sox4 cooperates with Evf1 in AKXD-23 myeloid tumors via transactivation of proviral LTR. *Blood* 2006;107:733–41.
14. Suzuki T, Shen H, Akagi K, et al. New genes involved in cancer identified by retroviral tagging. *Nat Genet* 2002;32:166–74.
15. Lund AH, Turner G, Trubetskoy A, et al. Genome-wide retroviral insertional tagging of genes involved in cancer in Cdkn2a-deficient mice. *Nat Genet* 2002;32:160–5.
16. Shin MS, Fredrickson TN, Hartley JW, Suzuki T, Agaki K, Morse HC III. High-throughput retroviral tagging for identification of genes involved in initiation and progression of mouse splenic marginal zone lymphomas. *Cancer Res* 2004;64:4419–27.
17. Dy P, Penzo-Mendez A, Wang H, Pedraza CE, Macklin WB, Lefebvre V. The three SoxC proteins-Sox4, Sox11 and Sox12-exhibit overlapping expression patterns and molecular properties. *Nucleic Acids Res* 2008;36:3101–17.
18. Pramoonjago P, Baras AS, Moskaluk CA. Knockdown of Sox4 expression by RNAi induces apoptosis in ACC3 cells. *Oncogene* 2006;25:5626–39.
19. Liao YL, Sun YM, Chau GY, et al. Identification of SOX4 target genes using phylogenetic footprinting-based prediction from expression microarrays suggests that overexpression of SOX4 potentiates metastasis in hepatocellular carcinoma. *Oncogene* 2008;27:5578–89.
20. Berger MF, Philippakis AA, Qureshi AM, He FS, Estep PW III, Bulky ML. Compact, universal DNA microarrays to comprehensively determine transcription-factor binding site specificities. *Nat Biotechnol* 2006;24:1429–35.
21. Bulky ML, Huang X, Choo Y, Church GM. Exploring the DNA-binding specificities of zinc fingers with DNA microarrays. *Proc Natl Acad Sci U S A* 2001;98:7158–63.
22. Mukherjee S, Berger MF, Jona G, et al. Rapid analysis of the DNA-binding specificities of transcription factors with DNA microarrays. *Nat Genet* 2004;36:1331–9.
23. McCabe CD, Spyropoulos DD, Martin D, Moreno CS. Genome-wide analysis of the homeobox C6 transcriptional network in prostate cancer. *Cancer Res* 2008;68:1988–96.
24. Odom DT, Zizlsperger N, Gordon DB, et al. Control of pancreas and liver gene expression by HNF transcription factors. *Science* 2004;303:1378–81.
25. Ren B, Robert F, Wyrick JJ, et al. Genome-wide location and function of DNA binding proteins. *Science* 2000;290:2306–9.
26. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2^{−(ΔΔC(T))} method. *Methods* 2001;25:402–8.
27. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. *Proc Natl Acad Sci U S A* 2001;98:5116–21.
28. Karanam S, Moreno CS. CONFAC: automated application of comparative genomic promoter analysis to DNA microarray datasets. *Nucleic Acids Res* 2004;32:W475–84.
29. Kel AE, Gossling E, Reuter I, Cheremushkin E, Kel-Margoulis OV, Wingender E. MATCH: a tool for searching transcription factor binding sites in DNA sequences. *Nucleic Acids Res* 2003;31:3576–9.
30. van de Wetering M, Oosterwegel M, van Norren K, Clevers H. Sox-4, an Sry-like HMG box protein, is a transcriptional activator in lymphocytes. *EMBO J* 1993;12:3847–54.
31. Wotton D, Lake RA, Farr CJ, Owen MJ. The high mobility group transcription factor, SOX4, transactivates the human CD2 enhancer. *J Biol Chem* 1995;270:7515–22.
32. Berger MF, Badis G, Gehrke AR, et al. Variation in homeodomain DNA binding revealed by high-resolution analysis of sequence preferences. *Cell* 2008;133:1266–76.
33. Dennis G, Jr., Sherman BT, Hosack DA, et al. DAVID: database for annotation, visualization, and integrated discovery. *Genome Biol* 2003;4:P3.
34. Pearson CA, Pearson D, Shibahara S, Hofsteenge J, Chiquet-Ehrismann R. Tenascin: cDNA cloning and induction by TGF-β. *EMBO J* 1988;7:2977–82.
35. Beiter K, Hiendlmeyer E, Brabletz T, et al. β-Catenin regulates the expression of tenascin-C in human colorectal tumors. *Oncogene* 2005;24:8200–4.
36. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. *Proc Natl Acad Sci U S A* 2005;102:15545–50.
37. Subramanian A, Kuehn H, Gould J, Tamayo P, Mesirov JP. GSEA-P: a desktop application for gene set enrichment analysis. *Bioinformatics* 2007;23:3251–3.
38. Ruebel KH, Leontovich AA, Tanizaki Y, et al. Effects of TGFβ1 on gene expression in the HP75 human pituitary tumor cell line identified by gene expression profiling. *Endocrine* 2008;33:62–76.
39. Zeller KI, Zhao X, Lee CW, et al. Global mapping of c-Myc binding sites and target gene networks in human B cells. *Proc Natl Acad Sci U S A* 2006;103:17834–9.
40. Ylostalo J, Smith JR, Pochampally RR, et al. Use of differentiating adult stem cells (marrow stromal cells) to identify new downstream target genes for transcription factors. *Stem Cells* 2006;24:642–52.
41. Geijsen N, Uings JJ, Pals C, et al. Cytokine-specific transcriptional regulation through an IL-5Rα interacting protein. *Science* 2001;293:1136–8.
42. Milne TA, Briggs SD, Brock HW, et al. MLL targets SET domain methyltransferase activity to Hox gene promoters. *Mol Cell* 2002;10:1107–17.
43. Chowdhury T, Brady HJ. Insights from clinical studies into the role of the MLL gene in infant and childhood leukemia. *Blood Cells Mol Dis* 2008;40:192–9.
44. Abate-Shen C, Banach-Petrosky WA, Sun X, et al. Nkx3.1; Pten mutant mice develop invasive prostate adenocarcinoma and lymph node metastases. *Cancer Res* 2003;63:3886–90.
45. Tavazoie SF, Alarcon C, Oskarsson T, et al. Endogenous human microRNAs that suppress breast cancer metastasis. *Nature* 2008;451:147–52.
46. Padua D, Zhang XH, Wang Q, et al. TGFβ primes breast tumors for lung metastasis seeding through angiopoietin-like 4. *Cell* 2008;133:66–77.
47. Wu X, Tu X, Joeng KS, Hilton MJ, Williams DA, Long F. Rac1 activation controls nuclear localization of β-catenin during canonical Wnt signaling. *Cell* 2008;133:340–53.
48. Robb GB, Rana TM. RNA helicase A interacts with RISC in human cells and functions in RISC loading. *Mol Cell* 2007;26:523–37.
49. Ambs S, Prueitt RL, Yi M, et al. Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer. *Cancer Res* 2008;68:6162–70.
50. Salaun B, Coste I, Risoan MC, Lebecque SJ, Renno T. TLR3 can directly trigger apoptosis in human cancer cells. *J Immunol* 2006;176:4894–901.
51. Ma L, Teruya-Feldstein J, Weinberg RA. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. *Nature* 2007;449:682–8.

Figures




Figure 1: DICER protein expression and cleaved, activated NOTCH1 is upregulated by SOX4. HA-SOX4 or vector control was transfected into LNCaP cells and immunoblots were probed for DICER, SOX4, cleaved NOTCH1, and PP2A as a loading control.




Figure 2: SOX4 Mice Genotyping. (Upper Panel) The presence of the upper band denotes the floxed, knockout allele while the presence of the lower band denotes the Wt allele. Control mice are heterozygous for the floxed SOX4 knockout allele (lane 1) while mice containing both floxed alleles have only the upper band (lane 2) and mice containing only the Wt allele have only the lower band (lane 3). (Lower Panel) All mice harbor the Probasin-Cre transgene as denoted by the presence of a single band.




Figure 3: (A) IHC stained section of control mouse prostate (4x). Clear glandular development is seen with slight hyperplasia. (B) IHC stained section of SOX4 knockout mouse prostate (4x). Clear hyperplasia is seen in the uppermost gland however the majority of tissue appears normal. (C) IHC stained section of SOX4 knockout mouse testis (4x). (D) IHC stained section of SOX4 knockout mouse testis (20x). Sperm production can be seen (black arrows) as slender black rods throughout the testis, suggesting the reproductive defect is not due to sperm production.